AIDS and Behavior

, Volume 15, Issue 1, pp 30–44 | Cite as

Reducing HIV-Related Risk Behaviors Among Injection Drug Users in Residential Detoxification

  • Robert E. Booth
  • Barbara K. CampbellEmail author
  • Susan K. Mikulich-Gilbertson
  • Carrie J. Tillotson
  • Dongseok Choi
  • James Robinson
  • Donald A. Calsyn
  • Raul N. Mandler
  • Lindsay M. Jenkins
  • Laetitia L. Thompson
  • Catherine L. Dempsey
  • Michael R. Liepman
  • Dennis McCarty
Original Paper


This study of 632 drug injectors enrolled in eight residential detoxification centers within the National Drug Abuse Treatment Clinical Trials Network tested three interventions to reduce drug and sex risk behaviors. Participants were randomized to: (a) a two-session, HIV/HCV counseling and education (C&E) model added to treatment as usual (TAU), (b) a one-session, therapeutic alliance (TA) intervention conducted by outpatient counselors to facilitate treatment entry plus TAU, or (c) TAU. Significant reductions in drug and sex risk behaviors occurred for all three conditions over a 6-month follow-up period. C&E participants reported significantly greater rates of attending an HIV testing appointment, but this was not associated with better risk reduction outcomes. Reporting treatment participation within 2 months after detoxification and self-efficacy to practice safer injection behavior predicted reductions in injection risk behaviors. Findings indicate that participation in detoxification was followed by significant decreases in drug injection and risk behaviors for up to 6-months; interventions added to standard treatment offered no improvement in risk behavior outcomes.


Drug injection Risk reduction Treatment entry Detoxification 



The authors thank the staff at the eight participating treatment centers and the patients who were involved in the study. Cooperative agreements from the National Institute on Drug Abuse supported the study design and implementation and the collection and analysis of the data: Great Lakes Node (U10 DA13710), Northern New England Node (U10 DA15831), Oregon/Hawaii Node (U10 DA13036), Rocky Mountain Node (U10 DA13716), and Pacific Northwest Node (U10 DA13714). The study also received support from the Oregon Clinical and Translational Research Institute (UL1 RR024140) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research.


  1. 1.
    National Research Council. AIDS: sexual behavior and intravenous drug use. Washington, DC: National Academy Press; 1989.Google Scholar
  2. 2.
    National Research Council, Institute of Medicine. In: Normand J, Vlahov D, Moses LE, editors. Preventing HIV transmission: the role of sterile needles and bleach. Washington, DC: National Academy Press; 1995.Google Scholar
  3. 3.
    CDC. Centers for Disease Control and Prevention: HIV/AIDS sero-surveillance report. Vol 18. Atlanta: CDC; 2008.Google Scholar
  4. 4.
    Knight KR, Purcell DW, Dawson-Rose C, Halkitis PN, Gomez CA, the Seropositive Urban Injectors Study Team. Sexual risk taking among HIV-positive injection drug users: contexts, characteristics, and implications for prevention. AIDS Educ Prev. 2005;17(1 suppl A):76–88.CrossRefPubMedGoogle Scholar
  5. 5.
    Kral A, Bluthenthal R, Lorvick J, Gee L, Bacchetti P, Edlin B. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet. 2001;357(9266):1397–401.CrossRefPubMedGoogle Scholar
  6. 6.
    Saxon AJ, Calsyn DA, Whittaker S. Freeman G. Sexual behaviors of intravenous drug users in treatment. J Acquir Immune Defic Syndr. 1991;4:938–44.PubMedGoogle Scholar
  7. 7.
    Watkins K, Metzger D, Woody G, McLellan A. Determinants of condom use among intravenous drug users. AIDS. 1993;7:719–23.CrossRefPubMedGoogle Scholar
  8. 8.
    Bulterys M, Chao A, Dushimimana A, et al. Multiple sexual partners and mother-to-child transmission of HIV-1. AIDS. 1993;7(12):1639–45.CrossRefPubMedGoogle Scholar
  9. 9.
    Battjes R, Pickens R, Amsel Z, Brown L. Heterosexual transmission of human immunodeficiency virus among intravenous drug users. J Infect Dis. 1990;162:1007–11.PubMedGoogle Scholar
  10. 10.
    Booth R, Koester S, Brewster J, Weibel W, Fritz R. Intravenous drug users and AIDS: risk behaviors. Am J Drug Alcohol Abuse. 1991;17(3):337–53.CrossRefPubMedGoogle Scholar
  11. 11.
    Murphy D. Heterosexual contacts of intravenous drug abusers: implications for the next spread of the AIDS epidemic. Adv Alcohol Subst Abuse. 1987;7(2):89–97.PubMedGoogle Scholar
  12. 12.
    Alter M. Hepatitis C virus infection in the United States. J Hepatol. 1999;31:88–91.CrossRefPubMedGoogle Scholar
  13. 13.
    Garfein R, Doherty M, Monterroso E, Thomas D, Nelson K, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:S11–9.PubMedGoogle Scholar
  14. 14.
    Coutinho R. HIV and hepatitis C among injecting drug users (editorial). Br Med J. 1998;317:424–5.Google Scholar
  15. 15.
    Crofts N, Caruana S, Kerger M, Bowden S. Hepatitis C on drug injecting equipment. Br Med J. 2000;321:899.CrossRefGoogle Scholar
  16. 16.
    Bortolotti F, Stivanello A, Dall’Armi A, Rinaldi R, La Grasta F. AIDS information campaign has significantly reduced risk factors for HIV infection in Italian drug abusers. J Acquir Immune Defic Syndr. 1988;1(4):412–3.PubMedGoogle Scholar
  17. 17.
    Power R, Hartnoll R, Daviaud E. Drug injecting, AIDS, and risk behaviour: potential for change and intervention strategies. Br J Addict. 1988;83(6):649–54.CrossRefPubMedGoogle Scholar
  18. 18.
    Booth R, Wiebel W. The effectiveness of reducing needle-related risks for HIV through indigenous outreach to injection drug users. Am J Addict. 1992;1(4):277–87.Google Scholar
  19. 19.
    Colon H, Robles R, Freeman D, Matos T. Effects of a HIV risk reduction education program among injection drug users in Puerto Rico. Puerto Rico Health Sci J. 1993;12(1):27–34.Google Scholar
  20. 20.
    Watters J, Downing M, Case P, Lorvick J, Cheng YT, Fergusson B. AIDS prevention for intravenous drug users in the community: street-based education and risk behavior. Am J Community Psychol. 1990;18(4):587–96.CrossRefPubMedGoogle Scholar
  21. 21.
    Calsyn DA, Saxon AJ, Freeman G. Lack of efficacy of AIDS education in reducing HIV high-risk transmission behaviors among injection drug users. Am J Public Health. 1992;82:573–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Casadonte P, Des Jarlais D, Friedman S, Rotrosen J. Psychological and behavioral impact among intravenous drug users of learning HIV test results. Int J Addict. 1990;25(4):409–26.PubMedGoogle Scholar
  23. 23.
    Skidmore C, Robertson J, Roberts J. Changes in HIV risk-taking behaviour in intravenous drug users: a second follow-up. Br J Addict. 1989;84:695–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Des Jarlais D, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet. 1996;348(9033):987–91.CrossRefPubMedGoogle Scholar
  25. 25.
    Watters J, Estilo M, Clark G. Syringe and needle exchange as HIV prevention for injection drug users. J Am Med Assoc. 1994;271:115–20.CrossRefGoogle Scholar
  26. 26.
    Corsi KF, Kwiatkowski CF, Booth RE. Predictors of positive outcomes for out-of-treatment opiate injectors recruited into methadone maintenance through street outreach. J Drug Issues. 2002;32(3):99–1016.Google Scholar
  27. 27.
    Hartgers C, van den Hoek A, Krijnen P, Coutinho RA. HIV prevalence and risk behavior among injecting drug users who participate in “low-threshold” methadone programs in Amsterdam. Am J Public Health. 1992;82(4):547–51.CrossRefPubMedGoogle Scholar
  28. 28.
    Metzger DS, Woody GE, McLellan AT, O’Brien CP, Druley P, Navaline H, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6:1049–56.PubMedGoogle Scholar
  29. 29.
    Moss AR, Vranizan K, Gorter R, Bacchetti P, Watters J, Osmong D. HIV seroconversion in intravenous drug users in San Francisco, 1985–1990. AIDS. 1994;8(2):223–31.CrossRefPubMedGoogle Scholar
  30. 30.
    Schwartz M, Baker G, Mulvey K, Plough A. Improving publicly funded substance abuse treatment: the value of case management. Am J Public Health. 1997;87:1659–64.CrossRefGoogle Scholar
  31. 31.
    Lundgren LM, Sullivan L, Amodeo M. How do treatment repeaters use the drug treatment system? An analysis of injection drug users in Massachusetts. J Subst Abus Treat. 2006;30:121–8.CrossRefGoogle Scholar
  32. 32.
    McCusker J, Bigelow C, Luippold R, Zorn M, Lewis BF. Outcomes of a 21-day drug detoxification program: retention, transfer to further treatment, and HIV risk reduction. Am J Drug Alcohol Abuse. 1995;21(1):1–16.CrossRefPubMedGoogle Scholar
  33. 33.
    Chutuape MA, Jasinski DR, Fingerhood MI, Stitzer ML. One-, three- and six-month outcomes after brief inpatient opioid detoxification. Am J Drug Alcohol Abuse. 2001;27:19–44.CrossRefPubMedGoogle Scholar
  34. 34.
    Coyle S. The NIDA HIV counseling and education intervention model: intervention manual. Atlanta: U.S. Department of Health and Human Services: GPO; 1993.Google Scholar
  35. 35.
    Campbell BK, Fuller BE, Lee ES, Tillotson C, Woelfel T, Jenkins L, et al. Facilitating outpatient treatment entry following detoxification for injection drug use: a multi-site test of three interventions. Psychol Addict Behav. 2009;23:260–70.CrossRefPubMedGoogle Scholar
  36. 36.
    NIDA. Risk behavior survey. 3rd ed. Rockville: Community Research Branch, National Institute on Drug Abuse; 1993.Google Scholar
  37. 37.
    Dowling-Guyer S, Johnson ME, Fisher DG, Needle RH, Watters JK, Andersen MD, et al. Reliability of drug users’ self-reported HIV risk behaviors and validity of self-reported recent drug use. Assessment. 1994;1(4):383–92.Google Scholar
  38. 38.
    Weatherby NL, Needle R, Cesari C, Booth RE, McCoy CB, Watters JK, et al. Validity of self-reported drug use among injection drug users and crack cocaine users recruited through street outreach. Eval Program Plan. 1994;17(4):347–55.CrossRefGoogle Scholar
  39. 39.
    Sobell LC, Sobell MB. Timeline followback user’s guide: a calendar method for assessing alcohol and drug use. Toronto: Addiction Research Foundation; 1996.Google Scholar
  40. 40.
    Booth RE, Lehman WE, Brewster JT, Sinitsyana L, Dvoryak S. Gender differences in sex risk behaviors among Ukraine injection users. J Acquir Immune Defic Syndr. 2007;46:112–7.PubMedGoogle Scholar
  41. 41.
    Booth RE, Kwitkowski CF, Stephens RC. Effectiveness of HIV/AIDS interventions on drug use and needle risk behaviors for out-of-treatment injection drug users. J Psychoactive Drugs. 1998;30(3):269–78.PubMedGoogle Scholar
  42. 42.
    Stephens RC, Kwiatkowski CF, Booth RE. The effectiveness of intervention efforts on HIV risky behaviors among injection drug users and crack smokers. In: Albrecht G, Levy J, editors. Advances in medical sociology. Greenwich: JAI Press; 2000.Google Scholar
  43. 43.
    Fiorentine R, Nakashima J, Anglin MD. Client engagement in drug treatment. J Subst Abus Treat. 1999;17:199–206.CrossRefGoogle Scholar
  44. 44.
    Connors GJ, Carroll KM, DiClemente CC, Longabaugh R, Donovan DM. The therapeutic alliance and its relationship to alcoholism treatment participation and outcome. J Consult Clin Psychol. 1997;65(4):588–98.CrossRefPubMedGoogle Scholar
  45. 45.
    De Weert-Van Oene GH, Schippers GM, De Jong CA, Schrijvers GJ. Retention in substance dependence treatment: the relevance of in-treatment factors. J Subst Abus Treat. 2001;20(4):253–61.CrossRefGoogle Scholar
  46. 46.
    Marmor M, Des Jarlais DC, Cohen H, Friedman SR, Beatrice ST, Dubin N, et al. Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. AIDS. 1987;1(1):39–44.PubMedGoogle Scholar
  47. 47.
    Mohl PC, Martinez D, Ticknor C, Huang M, O’Brien CP. Early dropouts from psychotherapy. J Nerv Ment Dis. 1991;179:478–81.CrossRefPubMedGoogle Scholar
  48. 48.
    Luborsky L, McLellan AT, Woody GE, O’Brien CP, Auerbach A. Therapist success and its determinants. Arch Gen Psychiatry. 1985;42:602–11.PubMedGoogle Scholar
  49. 49.
    Bordin ES. The generalizability of the psychoanalytic concept of the working alliance. Psychother Theory Res Pract. 1979;16:252–60.CrossRefGoogle Scholar
  50. 50.
    Craigie FC, Ross SM. The use of a videotape pretherapy training program to encourage treatment-seeking among alcohol detoxification patients. Behav Ther. 1980;11(2):141–7.CrossRefGoogle Scholar
  51. 51.
    Stark MJ, Kane BJ. General and specific psychotherapy role induction with substance-abusing clients. Int J Addict. 1985;20(8):1135–41.PubMedGoogle Scholar
  52. 52.
    Verinis JS. The effect of an orientation-to-treatment group on the retention of alcoholics in outpatient treatment. Subst Use Misuse. 1996;31(10):1423–31.CrossRefPubMedGoogle Scholar
  53. 53.
    SAS Institute, Inc. SAS Software Version 9.1 for Windows. Cary, NC: SAS Institute, Inc; 2004.Google Scholar
  54. 54.
    SAS Institute, Inc. SAS Software Version 9.2 for Windows. Cary, NC: SAS Institute, Inc; 2008.Google Scholar
  55. 55.
    Laird NM. Missing data in longitudinal studies. Stat Med. 1988;7:305–15.CrossRefPubMedGoogle Scholar
  56. 56.
    Jones RH. Longitudinal data with serial correlation: a state-space approach. New York: Chapman and Hall; 1993.Google Scholar
  57. 57.
    Koch GG, Gansky SA. Statistical considerations for multiplicity in confirmatory protocols. Drug Inf J. 1996;30:523–34.Google Scholar
  58. 58.
    Booth RE, Corsi KF, Mikulich-Gilbertson SK. Factors associated with methadone maintenance treatment retention among street-recruited injection drug users. Drug Alcohol Depend. 2004;74:177–85.CrossRefPubMedGoogle Scholar
  59. 59.
    Booth RE, Crowley TJ, Zhang Y. Substance abuse treatment entry, retention and effectiveness: out-of-treatment opiate injection users. Drug Alcohol Depend. 1996;42(1):11–20.CrossRefPubMedGoogle Scholar
  60. 60.
    Gibson DR, McCusker J, Chesney M. Effectiveness of psychosocial interventions in preventing HIV risk behavior in injecting drug users. AIDS. 1998;12:919–29.CrossRefPubMedGoogle Scholar
  61. 61.
    Gibson DR, Lovelle-Drache J, Young M, Hudes ES, Sorensen JL. Effectiveness of brief counseling in reducing HIV risk behavior in injecting drug users: final results of randomized trials of counseling with and without HIV testing. AIDS Behav. 1999;3(1):3–12.CrossRefGoogle Scholar
  62. 62.
    Booth RE, Lehman WE, Dvoryak JT, Brewster JT, Sinitsyna L. Interventions with injection drug users in Ukraine. Addiction. 2009;104:1864–73.CrossRefPubMedGoogle Scholar
  63. 63.
    Weinhardt LS, Carey MP, Johnson BT, Bickham NL. Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985–1997. Am J Public Health. 1999;89(9):1397–405.CrossRefPubMedGoogle Scholar
  64. 64.
    Prendergast ML, Urada D, Podus D. Meta-analysis of HIV risk-reduction interventions within drug abuse treatment programs. J Consult Clin Psychol. 2001;69:389–405.CrossRefPubMedGoogle Scholar
  65. 65.
    Semaan S, Des Jarlais DC, Sogolow E, Johnson WD, Hedges WD, Ramirez G, et al. A meta-analysis of the effect of HIV prevention interventions on the sex behaviors of drug users in the United States. J Acquir Immune Defic Syndr. 2002;30:S73–93.CrossRefPubMedGoogle Scholar
  66. 66.
    Sorenson J, Copeland A. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000;59:17–31.CrossRefGoogle Scholar
  67. 67.
    Booth RE, Corsi KF, Mikulich SK. Improving entry to methadone maintenance among out-of-treatment injection drug users. J Subst Abus Treat. 2003;24(4):305–11.CrossRefGoogle Scholar
  68. 68.
    John D, Kwiatkowski CF, Booth RE. Differences among out-of-treatment drug injectors who use stimulants only, opiates only or both: implications for treatment entry. Drug Alcohol Depend. 2001;64(2):165–72.CrossRefPubMedGoogle Scholar
  69. 69.
    Sitharthan T, Kavanagh DJ. Role of self-efficacy in predicting outcomes from a programme for controlled drinking. Drug Alcohol Depend. 1990;27:87–94.CrossRefGoogle Scholar
  70. 70.
    Reilly PM, Sees KL, Shopshire MS, Hall SM, Delucchi KL, Tusel DJ, et al. Self-efficacy and illicit opioid use in a 180-day methadone detoxification treatment. J Consult Clin Psychol. 1995;1:158–62.Google Scholar
  71. 71.
    Kleinman BP, Millery M, Scimeca M, Polissar NL. Predicting long-term treatment utilization among addicts entering detoxification: the contribution of help-seeking models. J Drug Issues. 2002;32(1):209–30.Google Scholar
  72. 72.
    Bouhnik AD, Preau M, Lert F, Peretti-Watel P, Schilz MA, Obadia Y, et al. Unsafe sex in regular partnerships among heterosexual persons living with HIV: evidence from a large representative sample of individuals attending outpatient services in France. AIDS. 2007;21:S57–62.CrossRefPubMedGoogle Scholar
  73. 73.
    Gollub EL, Rey D, Obadia Y, Moatti JP. Gender differences in risk behaviors among HIV+ persons with an IDU history: the link between partner characteristics and women’s higher drug-sex risks. Sex Transm Dis. 1998;25:483–8.CrossRefPubMedGoogle Scholar
  74. 74.
    Lollis CM, Strothers HS, Chitwood DD, McGhee M. Sex, drugs and HIV: does methadone maintenance reduce drug use and risky sexual behavior? J Behav Sci. 2000;23:545–557.Google Scholar
  75. 75.
    Booth RE. Gender differences in high-risk sex behaviors among heterosexual drug injectors and crack smokers. Am J Drug Alcohol Abuse. 1995;21:419–32.CrossRefPubMedGoogle Scholar
  76. 76.
    Booth RE, Koester SK, Pinto F. Gender differences in sex-risk behaviors, economic livelihood, and self-concept among drug injectors and crack smokers. Am J Addict. 1995;4:313–22.Google Scholar
  77. 77.
    Des Jarlais DC, Friedman SR, Goldsmith D, Hopkins W. Heterosexual transmission of human immunodeficiency virus from intravenous drug users: Regular partnerships and prostitution. In: Voeller B, Reinisch JMR, Gottleib M, editors. AIDS and sex. New York: Oxford University Press; 1990. p. 245–56.Google Scholar
  78. 78.
    Maisto S, McKay J, Conners G. Self-reported issues in substance abuse: state of the art and future directions. Behav Assess. 1990;121:117–34.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Robert E. Booth
    • 1
  • Barbara K. Campbell
    • 2
    Email author
  • Susan K. Mikulich-Gilbertson
    • 1
  • Carrie J. Tillotson
    • 3
  • Dongseok Choi
    • 2
  • James Robinson
    • 4
  • Donald A. Calsyn
    • 5
  • Raul N. Mandler
    • 8
  • Lindsay M. Jenkins
    • 6
    • 7
  • Laetitia L. Thompson
    • 1
  • Catherine L. Dempsey
    • 1
    • 9
  • Michael R. Liepman
    • 10
  • Dennis McCarty
    • 2
  1. 1.Department of PsychiatryUniversity of ColoradoDenverUSA
  2. 2.Department of Public Health and Preventive MedicineOregon Health and Science UniversityPortlandUSA
  3. 3.Oregon Clinical and Translational Research InstituteOregon Health and Science UniversityPortlandUSA
  4. 4.Nathan S. Kline Institute for Psychiatric ResearchOrangeburgUSA
  5. 5.Alcohol and Drug Abuse Institute and Department of Psychiatry & Behavioral SciencesUniversity of WashingtonSeattleUSA
  6. 6.Recovery Centers of King CountySeattleUSA
  7. 7.Alcohol and Drug Abuse InstituteUniversity of WashingtonSeattleUSA
  8. 8.Clinical Trials Network, National Institute on Drug AbuseBethesdaUSA
  9. 9.Department of PsychologyUniversity of ArizonaTucsonUSA
  10. 10.Department of PsychiatryMichigan State University/Kalamazoo Center for Medical StudiesKalamazooUSA

Personalised recommendations